AT8881 is our lead compound and has entered clinical development for the treatment of neuropathic pain. We have identified several other orally active peptides derived from LAT8881 that could have cost of goods or formulation advantages over LAT8881. We have also identified other compounds derived from different proteins with activity in spinal cord slice assays which provide additional IP. Once the LAT8881 target is identified we aim to perform HTS to identify new peptide and non-peptide leads as potential follow on compounds.
The potential for enhanced tissue repair suggested by the Mesenchymal Stem Cell differentiation and rabbit OA studies presents a potential additional opportunity for development of a treatment for Osteoarthritis.
Newly filed patents around backup compounds also provide the potential for Lateral Pharma to revisit the treatment of obesity.